BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//NYS Council for Community Behavioral Healthcare - ECPv5.9.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NYS Council for Community Behavioral Healthcare
X-ORIGINAL-URL:https://nyscouncil.org
X-WR-CALDESC:Events for NYS Council for Community Behavioral Healthcare
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240626T130000
DTEND;TZID=America/New_York:20240626T140000
DTSTAMP:20260525T032829
CREATED:20240604T163350Z
LAST-MODIFIED:20240604T163350Z
UID:12545-1719406800-1719410400@nyscouncil.org
SUMMARY:Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool
DESCRIPTION:Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool\nJune 26\, 1-2 p.m. ET\n\nRegister\n\n\nMortality due to alcohol-related liver disease (ALD) has risen steadily over the past two decades\, with a sharp increase during the COVID-19 pandemic. In 2022\, 46% of liver disease deaths among people ages 12 and older involved alcohol.\n\nDespite alcohol’s role in liver disease deaths\, medication treatments for alcohol use disorder (MAUD) are rarely used in patients with ALD\, in part because of stigma\, limited data on effectiveness\, and concerns about safety and further potential damage to the liver. There is an immense opportunity to increase use of MAUD for patients with or at risk of liver disease to tackle co-occurring health needs and prevent further complications or even death.\n\n\nJoin us June 26\, 1-2 p.m. ET for our latest PCSS-MAUD Webinar\, Medications for Alcohol Use Disorder in Patients with Liver Disease: Leveraging an Underutilized Tool to learn more about why and how MAUD can be useful when working with patients living with liver disease. Hear from two hepatologists who have successfully incorporated MAUD into their respective practices\, and how they are leveraging these medications to protect liver health.\n\nEducational Objectives:\n\nOutline the benefits of MAUD for patients with or at risk of liver disease.\nDescribe barriers to MAUD treatment for patients with or at risk of liver disease and explore ways to address these.\nDiscuss safe MAUD implementation among patients with liver disease.\n\n\nThe webinar will feature the following speakers:\n\nLamia Haque\, MD\, MPH\, Hepatologist\, Addiction Medicine Specialist\, Assistant Professor of Internal Medicine\, Yale School of Medicine\nGene Im\, MD\, FAASLD\, Transplant Hepatologist\, Associate Professor of Medicine\, Icahn School of Medicine\n\n  \nRegister
URL:https://nyscouncil.org/event/medications-for-alcohol-use-disorder-in-patients-with-liver-disease-leveraging-an-underutilized-tool/
END:VEVENT
END:VCALENDAR